Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    CEVOREM | meningioma
Previous Study | Return to List | Next Study

Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas (CEVOREM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02333565
Recruitment Status : Unknown
Verified January 2015 by Assistance Publique Hopitaux De Marseille.
Recruitment status was:  Recruiting
First Posted : January 7, 2015
Last Update Posted : January 7, 2015
Sponsor:
Information provided by (Responsible Party):
Assistance Publique Hopitaux De Marseille

Brief Summary:
To determine if combination of everolimus and octreotide exert an anti-tumoral activity in recurrent and/or aggressive meningiomas growth with limited adverse effects.

Condition or disease Intervention/treatment Phase
Recurrent Meningiomas Resistant Meningiomas Drug: Everolimus Drug: Octreotide Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.
Study Start Date : January 2015
Estimated Primary Completion Date : January 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Combinaison everolimus and octreotide Drug: Everolimus
Drug: Octreotide



Primary Outcome Measures :
  1. The Progression Free Survival rate [ Time Frame: 36 months ]
    Measured by the number of individuals without progression disease at 6 months, according to Response Assessment in Neuro-Oncology criteria's.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and Female patients ≥ 18 years old with no maximum limited of age
  • Histologically proven meningioma grade II and III; grade I meningioma may also be included, if progression is documented (see criteria 3), particularly in case of skull base location
  • Progression is defined on 2 different MRI as an increase of meningioma's surface ≥ 5% by 3 months period (i.e. an increase of 5% over 3 months, 10% over 6 months, 15% over 9 months…) or as the apparition of a new unequivocal neurological symptom related to the meningioma. We considered as a new unequivocal neurological symptom a new occurring neurological symptom as, for instance, hemiparesia, oculomotor nerve palsy, visual loss, facial nerve palsy, facial neuralgia, directly related to meningioma and suggesting meningioma growth with increase of meningioma compression on neurological structures despite no increasing size on MRIs.
  • Patients must have failed surgery, and not amenable to a new curative intended surgery
  • Patients must have failed radiotherapy and/or radiosurgery
  • Prior chemotherapy is allowed, if progression under the cytotoxic agent is clearly documented. An interval of 4 weeks after the last administration of the cytotoxic agent is warranted. Number of prior chemotherapies is not limited.
  • Patients who have given their written consent
  • Patients affiliated to a social insurance regime
  • Adequate bone marrow function as shown by: Absolute Neutrophil Count ≥ 1.5 x 109/L,
  • Platelets ≥ 100 x 109/L, Hb >9 g/dL
  • Adequate liver function as shown by; serum bilirubin ≤ 1.5 x Upper Limit of Normal; International Normalized Ratio < 1.3; alanine aminotransferase and aspartate aminotransferase ≤ 2.5 x Upper Limit of Normal - Adequate renal function: serum creatinine ≤ 1.5 x Upper Limit of Normal - Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L and fasting triglycerides ≤ 2.5 x Upper Limit of Normal. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after dyslipidemia treatment initiation.

Exclusion Criteria:

  • Patients with symptomatic lithiasis
  • Contra indication to octreotide and everolimus
  • Women of child-bearing age who are using no effective means of contraception
  • Pregnant or breast-feeding women or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes
  • Patients receiving other investigational agents or who received an investigative drug or therapy within the last 30 days.
  • Known intolerance or hypersensitivity to octreotide, everolimus or other rapamycin (sirolimus, temsirolimus)
  • Uncontrolled diabetes mellitus defined by HbA1c>8.5%
  • Patients who have any severe and/or uncontrolled medical condition:

unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to inclusion, serious uncontrolled cardiac arrhythmia, active or uncontrolled severe infection, cirrhosis, chronic active hepatitis or chronic persistent hepatitis, severely impaired lung function (spirometry and Diffusing Capacity of the lung for carbon monoxide 50% or less of normal and O2 saturation 88% or less at rest on room air), active, bleeding diathesis

  • Patients receiving chronic treatment with immunosuppressive agent
  • Patients with a known history of HIV seropositivity
  • Patients who have a history of another primary malignancy ≤ 3 years, with the exceptions of non-melanoma skin cancer, and carcinoma in situ of uterine cervix.
  • Females patients who are pregnant or lactating, or are of childbearing potential and not practicing a medically acceptable method of birth control.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02333565


Contacts
Layout table for location contacts
Contact: Urielle DESALBRES, Director 04.91.38.27.47 drci@ap-hm.fr

Locations
Layout table for location information
France
Assistance Publique Hôpitaux Marseille Recruiting
Marseille, France, 13354
Contact: Thomas GRAILLON, CCA    04.91.38.55.33    thomas.graillon@ap-hm.fr   
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Layout table for additonal information
Responsible Party: Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier: NCT02333565    
Other Study ID Numbers: 2014-09
2014-003694-42 ( EudraCT Number )
RCAPHM14_0080 ( Other Identifier: APHM )
First Posted: January 7, 2015    Key Record Dates
Last Update Posted: January 7, 2015
Last Verified: January 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Meningioma
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Vascular Tissue
Meningeal Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Nervous System Diseases
Everolimus
Octreotide
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Gastrointestinal Agents
Antineoplastic Agents, Hormonal